Login / Signup

Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer.

Taofeek Kunle OwonikokoGuojing ZhangHyun S KimRenea M StinsonRabih BecharaChao ZhangZhengjia ChenNabil F SabaSuchita PakkalaRathi PillaiXingming DengShi-Yong SunMichael R RossiGabriel L SicaSuresh S RamalingamFadlo R Khuri
Published in: Journal of translational medicine (2016)
Cisplatin inhibited growth of PDX derived from platinum-sensitive SCLC but was ineffective against PDX from platinum-refractory SCLC. Strong concordance between clinical and ex vivo effects of ASO and cisplatin in SCLC supports the use of PDX models to prescreen promising anticancer agents prior to clinical testing in SCLC patients. Trial Registration The study was registered at http://www.clinicaltrials.gov (NCT01470248).
Keyphrases